GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanobiotix SA (LTS:0QAV) » Definitions » Valuation Rank

Nanobiotix (LTS:0QAV) Valuation Rank


View and export this data going back to 2016. Start your Free Trial

What is Nanobiotix Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Nanobiotix Valuation Rank Related Terms

Thank you for viewing the detailed overview of Nanobiotix's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanobiotix Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanobiotix SA (LTS:0QAV) » Definitions » Valuation Rank
Comparable Companies
XPAR:OSE XPAR:IPH XPAR:GNFT XPAR:ALSEN XPAR:ALCLS XPAR:IVA XPAR:TNG XPAR:MAAT XPAR:DBV XPAR:ADOC VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
NBTX:USA NANO:France 5NR:Germany 5NR:Germany
Address
60 Rue de Wattignies, Paris, FRA, 75012
Website
https://www.nanobiotix.com
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.